Candel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data

MT Newswires Live

02/26

Candel Therapeutics (CADL) shares were down over 24% in recent trading on Tuesday after the company said three of seven patients with borderline resectable pancreatic ductal adenocarcinoma, or PDAC, who received CAN-2409 were still alive at the time of data cut-off.

The phase 2 study evaluated CAN-2409 plus valacyclovir together with standard-of-care chemoradiation, followed by resection, in patients with borderline resectable PDAC, according to the company.

The data cutoff date was Feb. 20 and median overall survival after enrollment was 31.4 months in the CAN-2409 group compared with 12.5 months in the control group.

Median survival after progression was 21.2 months in the CAN-2409 arm versus 7.2 months in the control arm, Candel added.

Price: 8.28, Change: -2.68, Percent Change: -24.45

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514282010"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514282010\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514282010?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 02:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514282010","market":"sh","top_or_hot":-1,"title":"Candel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data","media":"MT Newswires Live","content":"<html><body><p> Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CADL) shares were down over 24% in recent trading on Tuesday after the company said three of seven patients with borderline resectable pancreatic ductal adenocarcinoma, or PDAC, who received CAN-2409 were still alive at the time of data cut-off.</p><p>The phase 2 study evaluated CAN-2409 plus valacyclovir together with standard-of-care chemoradiation, followed by resection, in patients with borderline resectable PDAC, according to the company.</p><p>The data cutoff date was Feb. 20 and median overall survival after enrollment was 31.4 months in the CAN-2409 group compared with 12.5 months in the control group.</p><p>Median survival after progression was 21.2 months in the CAN-2409 arm versus 7.2 months in the control arm, Candel added.</p><p>Price: 8.28, Change: -2.68, Percent Change: -24.45</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-26 02:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CADL) shares were down over 24% in recent trading on Tuesday after the company said three of seven patients with borderline resectable pancreatic ductal adenocarcinoma, or PDAC, who received CAN-2409 were still alive at the time of data cut-off.</p><p>The phase 2 study evaluated CAN-2409 plus valacyclovir together with standard-of-care chemoradiation, followed by resection, in patients with borderline resectable PDAC, according to the company.</p><p>The data cutoff date was Feb. 20 and median overall survival after enrollment was 31.4 months in the CAN-2409 group compared with 12.5 months in the control group.</p><p>Median survival after progression was 21.2 months in the CAN-2409 arm versus 7.2 months in the control arm, Candel added.</p><p>Price: 8.28, Change: -2.68, Percent Change: -24.45</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4600","symbol_name":"加密货币概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514282010","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514282010","pubTimestamp":1740508505,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Candel Therapeutics  shares were down over 24% in recent trading on Tuesday after the company said three of seven patients with borderline resectable pancreatic ductal adenocarcinoma, or PDAC, who received CAN-2409 were still alive at the time of data cut-off.The phase 2 study evaluated CAN-2409 plus valacyclovir together with standard-of-care chemoradiation, followed by resection, in patients with borderline resectable PDAC, according to the company.The data cutoff date was Feb. 20 and median overall survival after enrollment was 31.4 months in the CAN-2409 group compared with 12.5 months in the control group.Median survival after progression was 21.2 months in the CAN-2409 arm versus 7.2 months in the control arm, Candel added.Price: 8.28, Change: -2.68, Percent Change: -24.45","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4600":"加密货币概念","BK4170":"电脑硬件、储存设备及电脑周边","LENZ":"Therapeutics","BK4139":"生物科技","BK4595":"比特币概念","BK4539":"次新股","BK4526":"热门中概股","CADL":"Candel Therapeutics, Inc."},"translate_title":"胰腺癌最终生存数据公布后，Candel Therapeutics股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"CADL":1},"content_text":"Candel Therapeutics (CADL) shares were down over 24% in recent trading on Tuesday after the company said three of seven patients with borderline resectable pancreatic ductal adenocarcinoma, or PDAC, who received CAN-2409 were still alive at the time of data cut-off.The phase 2 study evaluated CAN-2409 plus valacyclovir together with standard-of-care chemoradiation, followed by resection, in patients with borderline resectable PDAC, according to the company.The data cutoff date was Feb. 20 and median overall survival after enrollment was 31.4 months in the CAN-2409 group compared with 12.5 months in the control group.Median survival after progression was 21.2 months in the CAN-2409 arm versus 7.2 months in the control arm, Candel added.Price: 8.28, Change: -2.68, Percent Change: -24.45","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}